Interim results 2018 and perspective on activity. Read the Press Release
(WorldNews France)

Press release Biophytis : interim results 2018 and perspective on activity Paris (France), October 22, 2018, 6.00pm - BIOPHYTIS (Euronext Growth Paris: ALBPS), a biotechnology company specializing in the development of drug candidates to fight age-related degenerative diseases, announces the publication of its interim financial report and communicates the perspective on its activity until year-end. Stanislas Veillet, CEO of BIOPHYTIS, stated: "In the first half of 2018, key steps in the clinical programs of our drug candidate Sarconeos were completed, with the opening of the first clinical centers of the phase 2b study SARA-INT in Sarcopenia, and the Orphan Drug Designation for Duchenne...